Skandinaviska Enskilda Banken AB publ Grows Stock Holdings in Stryker Co. (NYSE:SYK)

Skandinaviska Enskilda Banken AB publ boosted its stake in shares of Stryker Co. (NYSE:SYK) by 61.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 165,820 shares of the medical technology company’s stock after acquiring an additional 63,297 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in Stryker were worth $60,070,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Kohmann Bosshard Financial Services LLC acquired a new position in Stryker in the 4th quarter worth about $25,000. Dunhill Financial LLC boosted its stake in shares of Stryker by 94.9% in the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 37 shares during the last quarter. Rakuten Securities Inc. raised its stake in Stryker by 618.2% in the 4th quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock valued at $28,000 after purchasing an additional 68 shares during the last quarter. Centricity Wealth Management LLC purchased a new position in Stryker in the 4th quarter valued at $30,000. Finally, BankPlus Trust Department acquired a new stake in Stryker during the 4th quarter worth $33,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $442.00 target price on shares of Stryker in a research report on Wednesday, January 29th. Stifel Nicolaus raised their target price on shares of Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a research note on Wednesday, January 29th. JMP Securities reaffirmed a “market perform” rating on shares of Stryker in a report on Tuesday, February 18th. Citigroup reissued a “buy” rating and set a $450.00 price objective on shares of Stryker in a research note on Wednesday, February 26th. Finally, The Goldman Sachs Group set a $422.00 target price on Stryker in a research note on Tuesday, March 4th. Five research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $421.90.

Stryker Price Performance

Stryker stock opened at $363.52 on Thursday. The company’s 50 day moving average is $382.76 and its two-hundred day moving average is $373.33. The firm has a market cap of $138.71 billion, a PE ratio of 46.85, a price-to-earnings-growth ratio of 2.93 and a beta of 0.95. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. Stryker Co. has a 52-week low of $314.93 and a 52-week high of $406.19.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period last year, the firm earned $3.46 earnings per share. On average, research analysts expect that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.92%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s dividend payout ratio (DPR) is 43.30%.

Insider Transactions at Stryker

In related news, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the sale, the director now directly owns 3,642,075 shares in the company, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the sale, the director now owns 14,895 shares in the company, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.